News

The more we know, the more we achieve.

Our media.

Beta Bionics Announces FDA Clearance and Commercialization of the iLet Bionic Pancreas

- First and only, automated insulin-delivery system that determines…

Beta Bionics Appoints Dr. Steven Russell as Chief Medical Officer in Preparation for the Commercial Launch of the iLet Bionic Pancreas System

Caution: The iLet Bionic Pancreas is an investigational device…

Beta Bionics Appoints Sean Saint as CEO and Board Member

Caution: The iLet® Bionic Pancreas and iLet Duo™ are investigational…

The Insulin-Only Bionic Pancreas Pivotal Trial Showed Consistent Mean HbA1c Reductions Across a Variety of Subgroups at ADA’s 82nd Scientific Sessions

Caution: The iLet® Bionic Pancreas is an investigational device…

The iLet® Bionic Pancreas Significantly Reduced HbA1c and Improved Time in Range vs Standard of Care for a Diverse Range of People with Type 1 Diabetes

Caution: The iLet® Bionic Pancreas is an investigational device…

Pivotal Trial Results of the iLet® Bionic Pancreas To Be Presented at ATTD

Caution: The iLet® Bionic Pancreas is an investigational device…

Beta Bionics Announces Closing of $57 Million Series C Financing

Caution: The iLet® Bionic Pancreas is an investigational device…

Beta Bionics Announces Data Lock of the Insulin-Only Bionic Pancreas Pivotal Trial and Enrollment into the Screening Protocol of the Bihormonal Bionic Pancreas Pivotal Trial

The iLet® Bionic Pancreas is an investigational device limited…

Beta Bionics Announces Appointment of Christy Jones to Board of Directors

Irvine, CA – May 6, 2021 – Beta Bionics, Inc., a medical…

Beta Bionics appoints Martha Aronson and Sean Carney to its Board as Independent Directors

West Concord, MA – February 20, 2020 – Beta Bionics, Inc.…

Beta Bionics and Zealand Pharma announce superior glycemic control in phase 2 home-use clinical trial testing the iLet™ Bionic Pancreas using dasiglucagon

First home-use trial of the iLet Bionic Pancreas System using…

Beta Bionics and Zealand Pharma initiate home-use trial of the iLet™ bionic pancreas with dasiglucagon for autonomous bihormonal treatment of Type 1 diabetes

First home-use trial of the bihormonal iLet Bionic Pancreas…

Beta Bionics secures an initial $50 million Series B round

The round was led by Eventide Asset Management Other institutional…

Beta Bionics Announces Start of Home-Use Clinical Trials with the iLet™ Bionic Pancreas System and Receives IDE Approval from the FDA to Expand its Clinical Trials to Include the Senseonics Eversense CGM Integrated into the iLet

The Beta Bionics iLet Bionic Pancreas System is now approved…

Beta Bionics Receives IDE Approval from the FDA to Begin a Home-Use Clinical Trial Testing the New iLet™ Bionic Pancreas System

First trial to test Fiasp® – Novo Nordisk’s latest formulation…

Zealand and Beta Bionics to collaborate on the development of a first-in-class dual-hormonal bionic pancreas system for treatment of people with type 1 diabetes

Synergistic match of Beta Bionics’s dual-hormonal, artificial,…

Beta Bionics Announces FDA Clearance and Commercialization of the iLet Bionic Pancreas

- First and only, automated insulin-delivery system that determines…

Beta Bionics Appoints Dr. Steven Russell as Chief Medical Officer in Preparation for the Commercial Launch of the iLet Bionic Pancreas System

Caution: The iLet Bionic Pancreas is an investigational device…

Beta Bionics Appoints Sean Saint as CEO and Board Member

Caution: The iLet® Bionic Pancreas and iLet Duo™ are investigational…

The Insulin-Only Bionic Pancreas Pivotal Trial Showed Consistent Mean HbA1c Reductions Across a Variety of Subgroups at ADA’s 82nd Scientific Sessions

Caution: The iLet® Bionic Pancreas is an investigational device…

The iLet® Bionic Pancreas Significantly Reduced HbA1c and Improved Time in Range vs Standard of Care for a Diverse Range of People with Type 1 Diabetes

Caution: The iLet® Bionic Pancreas is an investigational device…

Pivotal Trial Results of the iLet® Bionic Pancreas To Be Presented at ATTD

Caution: The iLet® Bionic Pancreas is an investigational device…

Beta Bionics Announces Closing of $57 Million Series C Financing

Caution: The iLet® Bionic Pancreas is an investigational device…

Beta Bionics Announces Data Lock of the Insulin-Only Bionic Pancreas Pivotal Trial and Enrollment into the Screening Protocol of the Bihormonal Bionic Pancreas Pivotal Trial

The iLet® Bionic Pancreas is an investigational device limited…

Beta Bionics Announces Appointment of Christy Jones to Board of Directors

Irvine, CA – May 6, 2021 – Beta Bionics, Inc., a medical…

Beta Bionics appoints Martha Aronson and Sean Carney to its Board as Independent Directors

West Concord, MA – February 20, 2020 – Beta Bionics, Inc.…

Beta Bionics and Zealand Pharma announce superior glycemic control in phase 2 home-use clinical trial testing the iLet™ Bionic Pancreas using dasiglucagon

First home-use trial of the iLet Bionic Pancreas System using…

Beta Bionics and Zealand Pharma initiate home-use trial of the iLet™ bionic pancreas with dasiglucagon for autonomous bihormonal treatment of Type 1 diabetes

First home-use trial of the bihormonal iLet Bionic Pancreas…

Beta Bionics secures an initial $50 million Series B round

The round was led by Eventide Asset Management Other institutional…

Beta Bionics Announces Start of Home-Use Clinical Trials with the iLet™ Bionic Pancreas System and Receives IDE Approval from the FDA to Expand its Clinical Trials to Include the Senseonics Eversense CGM Integrated into the iLet

The Beta Bionics iLet Bionic Pancreas System is now approved…

Beta Bionics Receives IDE Approval from the FDA to Begin a Home-Use Clinical Trial Testing the New iLet™ Bionic Pancreas System

First trial to test Fiasp® – Novo Nordisk’s latest formulation…

Zealand and Beta Bionics to collaborate on the development of a first-in-class dual-hormonal bionic pancreas system for treatment of people with type 1 diabetes

Synergistic match of Beta Bionics’s dual-hormonal, artificial,…

Beta Bionics Announces FDA Clearance and Commercialization of the iLet Bionic Pancreas

- First and only, automated insulin-delivery system that determines…

Beta Bionics Appoints Dr. Steven Russell as Chief Medical Officer in Preparation for the Commercial Launch of the iLet Bionic Pancreas System

Caution: The iLet Bionic Pancreas is an investigational device…

Beta Bionics Appoints Sean Saint as CEO and Board Member

Caution: The iLet® Bionic Pancreas and iLet Duo™ are investigational…

The Insulin-Only Bionic Pancreas Pivotal Trial Showed Consistent Mean HbA1c Reductions Across a Variety of Subgroups at ADA’s 82nd Scientific Sessions

Caution: The iLet® Bionic Pancreas is an investigational device…

The iLet® Bionic Pancreas Significantly Reduced HbA1c and Improved Time in Range vs Standard of Care for a Diverse Range of People with Type 1 Diabetes

Caution: The iLet® Bionic Pancreas is an investigational device…

Pivotal Trial Results of the iLet® Bionic Pancreas To Be Presented at ATTD

Caution: The iLet® Bionic Pancreas is an investigational device…

Beta Bionics Announces Closing of $57 Million Series C Financing

Caution: The iLet® Bionic Pancreas is an investigational device…

Beta Bionics Announces Data Lock of the Insulin-Only Bionic Pancreas Pivotal Trial and Enrollment into the Screening Protocol of the Bihormonal Bionic Pancreas Pivotal Trial

The iLet® Bionic Pancreas is an investigational device limited…

Beta Bionics Announces Appointment of Christy Jones to Board of Directors

Irvine, CA – May 6, 2021 – Beta Bionics, Inc., a medical…

Beta Bionics appoints Martha Aronson and Sean Carney to its Board as Independent Directors

West Concord, MA – February 20, 2020 – Beta Bionics, Inc.…

Beta Bionics and Zealand Pharma announce superior glycemic control in phase 2 home-use clinical trial testing the iLet™ Bionic Pancreas using dasiglucagon

First home-use trial of the iLet Bionic Pancreas System using…

Beta Bionics and Zealand Pharma initiate home-use trial of the iLet™ bionic pancreas with dasiglucagon for autonomous bihormonal treatment of Type 1 diabetes

First home-use trial of the bihormonal iLet Bionic Pancreas…

Beta Bionics secures an initial $50 million Series B round

The round was led by Eventide Asset Management Other institutional…

Beta Bionics Announces Start of Home-Use Clinical Trials with the iLet™ Bionic Pancreas System and Receives IDE Approval from the FDA to Expand its Clinical Trials to Include the Senseonics Eversense CGM Integrated into the iLet

The Beta Bionics iLet Bionic Pancreas System is now approved…

Beta Bionics Receives IDE Approval from the FDA to Begin a Home-Use Clinical Trial Testing the New iLet™ Bionic Pancreas System

First trial to test Fiasp® – Novo Nordisk’s latest formulation…

Zealand and Beta Bionics to collaborate on the development of a first-in-class dual-hormonal bionic pancreas system for treatment of people with type 1 diabetes

Synergistic match of Beta Bionics’s dual-hormonal, artificial,…

Beta Bionics is a public benefit corporation.

We are committed to balancing purpose with profit and giving back to society as we fulfill our public benefit mission.

Safety Information – The iLet Bionic Pancreas System is indicated for use by people with type 1 diabetes 6 years of age and older. The iLet Bionic Pancreas requires prescription by a physician. Refer to the iLet Bionic Pancreas System User Guide at www.betabionics.com/resouces/user-guides, or for complete safety information including indications, contraindications, warnings, cautions, compatible devices, compatible drugs and instructions, refer to www.betabionics.com/resources/safety. DO NOT start to use the iLet Bionic Pancreas System without adequate training. Incorrect use may result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.

Medical Disclaimer – This website is for information only and is not a substitute for medical advice and/or services from a healthcare provider. All personal health care decisions and treatment should be discussed with a healthcare provider who is familiar with your individual needs.

Copyright © 2023 Beta Bionics | Privacy Policy | Terms of Use | Cookies